The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.
News
The latest news from Retina UK. Please use the filters to find the articles which interest you.
CRISPR gene editing leads to improvements in vision for people with inherited blindness, clinical trial shows.
New Young Persons Project from Retina UK
We are proud to launch our new Young Persons Project, which will play a significant role in providing impactful and timely support for young people with inherited sight loss and mental health challenges, across the UK.
New Gene Insertion Therapy for Stargard Disease in Development
SalioGen Developing Novel Gene Insertion Therapy for Stargardt disease.
Grant from The National Lottery Community Fund
We regularly make applications for grants to fund our information and support projects and have recently been successful in securing £12,000 from The National Lottery Community Fund.
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Vitamin A supplements provides no vision benefit to RP patients
Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).